FDA Inspection 1180833 — Novartis Pharma AG
The FDA completed an inspection of Novartis Pharma AG on August 30, 2022 in Basel. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 30, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Basel (Switzerland)